Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.41 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.41 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30341869 | 1.00 | ADRB2 (0.45) | ADRB2L3MBTL1TDP1PRMT5WDR77 | |
| SCHEMBL7798917 | 1.00 | ADRB2 (0.45) | ADRB2L3MBTL1TDP1PRMT5WDR77 | |
| SCHEMBL719851 | 1.00 | ADRB2 (0.45) | ADRB2L3MBTL1TDP1PRMT5WDR77 | |
| SCHEMBL18415198 | 0.88 | ADRB2 (0.45) | ADRB2L3MBTL1TDP1PRMT5WDR77 | |
| SCHEMBL21141440 | 0.88 | ADRB2 (0.45) | ADRB2L3MBTL1TDP1PRMT5WDR77 | |
| SCHEMBL3978396 | 0.86 | ADRB2 (0.43) | ADRB2L3MBTL1TDP1PRMT5WDR77 | |
| SCHEMBL2456888 | 0.84 | ADRB3 (0.53) | ADRB2ADRB3 | |
| SCHEMBL7119142 | 0.84 | ADRB3 (0.53) | ADRB2ADRB3 | |
| SCHEMBL6074905 | 0.84 | ADRB3 (0.53) | ADRB2ADRB3 | |
| SCHEMBL5742454 | 0.83 | L3MBTL1 (0.44) | ADRB2L3MBTL1TDP1FOLH1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873909-B | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-115873909-A | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115873909-B | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115873909-B | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115873909-A | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115873909-A | Preparation method of arformoterol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-107074833-B | Having beta2Benzo ring derivatives with receptor agonistic and M3 receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3375781-A1 | BENZO RING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2018-09-19 | — | — | EP | disclosed |
| EP-3012254-B1 | BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS | THERAVANCE RESPIRATORY CO LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2017012489-A1 | BENZO RING DERIVATIVE WITH Β2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2017-01-26 | — | — | WO | disclosed |
| WO-2004106279-A2 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106333-A1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242622-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004089892-A2 | DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074246-A2 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | HCAR2, CHRM3, BDKRB2 | ADRB2 10/4885L3MBTL1 2392/4885TDP1 3818/4885 |
| US-20040242622-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA1B | ADRB2 2/4885L3MBTL1 3218/4885TDP1 3978/4885 |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885L3MBTL1 2489/4885TDP1 4437/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885L3MBTL1 2462/4885TDP1 4436/4885 |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | ADRA2C, ADRB2, AHR | ADRB2 2/4885L3MBTL1 1655/4885TDP1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.